Inosine pranobex
|
WikiDoc Resources for Inosine pranobex |
|
Articles |
|---|
|
Most recent articles on Inosine pranobex Most cited articles on Inosine pranobex |
|
Media |
|
Powerpoint slides on Inosine pranobex |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Inosine pranobex at Clinical Trials.gov Trial results on Inosine pranobex Clinical Trials on Inosine pranobex at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Inosine pranobex NICE Guidance on Inosine pranobex
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Inosine pranobex Discussion groups on Inosine pranobex Patient Handouts on Inosine pranobex Directions to Hospitals Treating Inosine pranobex Risk calculators and risk factors for Inosine pranobex
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Inosine pranobex |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Inosine pranobex (Isoprinosine or Methisoprinol) is a combinatinon of inosine, acetamidobenzoic acid, and dimethylaminoisopropanol used as an antiviral drug. Inosine pranobex has no effect on viral particles itself. It acts as a immunostimulant, an analog of thymus hormones.[1] It is most commonly used to treat the rare measles complication subacute sclerosing panencephalitis in conjunction with intrathecal interferon therapy.[2]
References
- ↑ American Cancer Society. "Inosine Pranobex". Retrieved 31 July 2013.
- ↑ Campoli-Richards DM, Sorkin EM, Heel RC. (Nov 1986). "Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy". Drugs. 32 (5): 383–424. doi:10.2165/00003495-198632050-00001.